Lucid Psycheceuticals Inc.
Tracked across 5 events · 33 articles · First seen Jun 02, 2026 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Lucid Psycheceuticals Inc. is a wholly owned subsidiary of Quantum BioPharma and is focused on the research and development of Lucid-MS.
Jun 08, 2026 · 8 articles
Business
Quantum BioPharma Ltd. announced the grant of 572,500 stock options to directors, officers, employees, and consultants. Each option is exercisable at C$4.80 for five years, expiring August 20, 2031. Of these, 172,500 vested immediately, and…
Impact: Lucid Psycheceuticals Inc. is a wholly owned subsidiary of Quantum BioPharma, mentioned as the developer of Lucid-MS. The stock option grant does not directly affect Lucid, but it is part of the parent company's corporate update.
Aug 21, 2026 · 6 articles
Business
Impact: Lucid Psycheceuticals Inc. is a wholly owned subsidiary of Quantum BioPharma Ltd. focused on research and development of Lucid-MS.
Jun 02, 2026 · 6 articles
Business
Impact: Lucid Psycheceuticals Inc. is a wholly owned subsidiary of Quantum BioPharma focused on Lucid-MS. It is mentioned in the background but not directly involved in the event.
Jul 07, 2026 · 6 articles
Business
Impact: Lucid Psycheceuticals Inc. is a wholly owned subsidiary of Quantum BioPharma focused on Lucid-MS, but not directly involved in the debt settlement.
Jul 20, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Lucid Psycheceuticals Inc. live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard